According to company officials, the new system was designed, tested and approved for use with magnetic resonance imaging (MRI) under specified scanning conditions, and is now commercially available in select European countries. Patients receiving the EnRhythm MRI SureScan Pacing System will for be able to undergo MRI scans under certain conditions, representing a major milestone in the evolution of implantable cardiac devices.
"MRI is an invaluable medical diagnostic tool for many common diseases and conditions that, until now, patients with implanted pacemakers have been prohibited from receiving," said Alain Coudray, M.D., Medtronic's vice president of the Cardiac Rhythm Disease Management business in Western Europe. "Medtronic recognizes the complex needs of today's patient and will continue to develop advancements in pacemaker technology and other devices that allow patients to receive optimal medical care."
Medtronic noted that approximately 2 million Europeans have implanted pacemakers, but these patients are prohibited from receiving MRI scans, a diagnostic method for many common diseases and conditions, because their device could interact with MRI machines, potentially affecting the device or patient safety. According to estimates, 50-75 percent of patients worldwide with implanted cardiac devices are expected to need an MRI scan during the lifetime of their devices1.
Medtronic is involved in medical technology.
((Comments on this story may be sent to newsdesk@closeupmedia.com))
((Distributed via M2 Communications Ltd - http://www.m2.com))
http://www.10meters.com
Comments on this story may be sent to newsdesk@closeupmedia.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index